Oral administration of bergenin (50 mg/kg), 5-ASA (100 mg/kg) and rosiglitazone (20 mg/kg) significantly improved disease symptoms of mice with colitis, including reducing DAI score and MPO activity, rescuing the shortening of colon length, and alleviating histopathological changes in colons. This evidence concerns the gene MPO and colitis.